MS and post-traumatic stress – an invitation to collaborate on a new project
Shift.ms and Barts MS are looking for collaborators to develop and implement a project or audit around post-traumatic stress disorder (PTSD) in multiple sclerosis (MS). Shift.ms have been aware of PTSD as having a role in MS after looking at post-traumatic growth at an event in London several years ago. Since that time, Shift.ms have […]
White paper from Shift.MS outlines COVID’s ongoing impact on MS community
MS online community Shift.MS have published a white paper detailing the ongoing impact of COVID-19 on the MS community as reported by people living with MS themselves. Sending out an online survey in September this year, Shift.MS received almost 1,500 responses and have used this to inform the white paper, as well as to develop a short awareness video, and […]
MS Advanced MasterClass project winner announced!
This week our MS Advanced MasterClass took place and nine delegates gave virtual presentations of their projects. The winning project was presented by Chandni Radia, a lead neuroscience pharmacist based at Imperial College Healthcare NHS Trust. Her work focussed on prevention of risk in ocrelizumab through early B-cell monitoring. Her review of 170 people with […]
ADIOS – adaptive ocrelizumab dosing study
Dear MS Academy Member, We are exploring a funding application to perform an Adaptive Ocrelizumab Dosing Study or ADIOS trial. The idea is to try and adjust the dosing regimen of ocrelizumab to derisk some of the emerging adverse events associated with long-term B cell depletion. Would you be interested in participating? If yes, do you mind completing the […]
International Virtual MasterClass – the first of its kind!
Our first ever International Virtual MasterClass ran last month over a period of two weeks, attended by 53 healthcare professionals from around the globe. Co-created by Roche Egypt, the MasterClass was specifically focussed on multiple sclerosis (MS), and provided a virtual learning experience for delegates across 10 countries (table 1) where specialists in the condition […]
COVID vaccines have implications for MS disease-modifying therapies
“Vaccine readiness” has become a hot topic in MS, which is often treated with immunosuppressive drugs. In a recent webinar (held on 21st May) hosted by MS Academy, Professor Gavin Giovannoni and Professor David Baker discussed the likelihood of people living with MS being able to respond to a COVID-19 vaccine. At that time, just […]
Essential neurorehabilitation in the aftermath of COVID-19
The impact of coronavirus on our health service has been highly documented, but with the first wave passed, the burden has not lifted, but altered, in the form of rehabilitation. Earlier this week, we highlighted an article in Reuters which has since been echoed in multiple publications – the long-term implications of COVID-19 on a […]
Are the ‘Forgotten Many’ forgotten again? NICE rejects Novartis’ Mayzent for SPMS
Before we, as the MS Academy, respond to NICE it is important we do a short survey to find out what the situation is on the ground and see if there is any consensus in our practice. We would appreciate it if you spend 2 to 4 minutes completing the following survey. Survey The National […]
World MS Day 2020
World MS is officially marked on 30th May. It brings the global MS community together to share stories, raise awareness and campaign with everyone affected by multiple sclerosis (MS). World MS Day activities take place throughout the month of May and in early June. The campaign offers flexibility for individuals and organisations to achieve a […]
Fampyra approved in Scotland
The Scottish Medicines Consortium (SMC) have approved ‘Fampyra’ for use by people living with multiple sclerosis (MS) in Scotland. Around 2 in 3 people with MS will develop walking difficulties and the drug, fampridine, improves walking ability in those responsive to it; around 1 in 3 people who try it (Biogen). Developed by Biogen Idec, […]